Foundayo (orforglipron) is an FDA-approved daily oral GLP-1 receptor agonist from Eli Lilly, launched in April 2026 for chronic weight management in adults with obesity or overweight. As a non-peptide small molecule, it works without food/water restrictions and showed up to 11.1% weight loss in 72-week trials. Product image will be sent upon request as we do not share images on our post. They come in vials and we have lab test result from other clients. Make sure you join the signal channel for update

We offer full reship when it does not arrive. We always accept escrow orders. We are here to fulfill your dreams.